C-Tri to speed up R&D for new drugs.

Published: 2002-09-03 06:56:00

Updated: 2002-09-03 06:56:00

C-Tri Co., a bio-tech venture company (www.c-tri.com) plans to have a temporary shareholder's meeting on Aug. 23 to ratify the M&A with Chirogene after taking over Chirogene Co., another bio-tech venture company having a technology for the photo active compound synthesis. The merger has made in a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK